Andrii Buvailo, PhD
@abuv.bsky.social
I write about AI in drug discovery/biotech, aging research, and GLP-1 medicines | Co-founder www.BiopharmaTrend.com | newsletters: Where Tech Meets Bio (www.TechLifeSci.com) and Molecules & Empires.
Eli Lilly recently became the first pharmaceutical company in history to cross a $1 trillion market valuation.
The main driver wasn’t oncology or gene therapy.
It was a class of metabolic drugs known as GLP-1 receptor agonists.
The main driver wasn’t oncology or gene therapy.
It was a class of metabolic drugs known as GLP-1 receptor agonists.
February 12, 2026 at 5:03 PM
Eli Lilly recently became the first pharmaceutical company in history to cross a $1 trillion market valuation.
The main driver wasn’t oncology or gene therapy.
It was a class of metabolic drugs known as GLP-1 receptor agonists.
The main driver wasn’t oncology or gene therapy.
It was a class of metabolic drugs known as GLP-1 receptor agonists.
Here are 3 real-life AI uses beyond the drug discovery hype, according to Diogo Rau, CIDO at Eli Lilly.
With Lilly announcing a $1B AI innovation lab with Nvidia, most headlines focused on AI-powered drug discovery.
With Lilly announcing a $1B AI innovation lab with Nvidia, most headlines focused on AI-powered drug discovery.
February 11, 2026 at 9:59 PM
Here are 3 real-life AI uses beyond the drug discovery hype, according to Diogo Rau, CIDO at Eli Lilly.
With Lilly announcing a $1B AI innovation lab with Nvidia, most headlines focused on AI-powered drug discovery.
With Lilly announcing a $1B AI innovation lab with Nvidia, most headlines focused on AI-powered drug discovery.
The one career move that gave me more leverage than my PhD...
medium.com/@editor_243...
medium.com/@editor_243...
February 11, 2026 at 4:56 PM
The one career move that gave me more leverage than my PhD...
medium.com/@editor_243...
medium.com/@editor_243...
Here’s a thought I can’t unsee:
You are not a single organism.
You’re a biological ecosystem — 30 trillion human cells coexisting with 40 trillion microbes.
This changes everything about how we think about aging. 🧵
You are not a single organism.
You’re a biological ecosystem — 30 trillion human cells coexisting with 40 trillion microbes.
This changes everything about how we think about aging. 🧵
February 10, 2026 at 1:29 PM
Here’s a thought I can’t unsee:
You are not a single organism.
You’re a biological ecosystem — 30 trillion human cells coexisting with 40 trillion microbes.
This changes everything about how we think about aging. 🧵
You are not a single organism.
You’re a biological ecosystem — 30 trillion human cells coexisting with 40 trillion microbes.
This changes everything about how we think about aging. 🧵
When it comes to China, nothing is to be taken lightly…
Here is a nice brief from the BiopharmaTrend team about recent activity and notable players in the West-China biotech scene.
www.techlifesci.com/p/big-pharm...
Here is a nice brief from the BiopharmaTrend team about recent activity and notable players in the West-China biotech scene.
www.techlifesci.com/p/big-pharm...
Big Pharma’s China Deal Wave & 12 Companies on Our Radar
A snap look at some of the deal dynamics and company platforms pulling global pharma toward China
www.techlifesci.com
February 10, 2026 at 4:57 AM
When it comes to China, nothing is to be taken lightly…
Here is a nice brief from the BiopharmaTrend team about recent activity and notable players in the West-China biotech scene.
www.techlifesci.com/p/big-pharm...
Here is a nice brief from the BiopharmaTrend team about recent activity and notable players in the West-China biotech scene.
www.techlifesci.com/p/big-pharm...
China's biotech scene is no joke. Check out this sharp update from the BiopharmaTrend team, spotlighting key movements and standout players in the West-China biotech landscape. Dive in here: www.techlifesci.com/p/big-pharm...
Big Pharma’s China Deal Wave & 12 Companies on Our Radar
A snap look at some of the deal dynamics and company platforms pulling global pharma toward China
www.techlifesci.com
February 9, 2026 at 10:00 PM
China's biotech scene is no joke. Check out this sharp update from the BiopharmaTrend team, spotlighting key movements and standout players in the West-China biotech landscape. Dive in here: www.techlifesci.com/p/big-pharm...
GLP-1s started as diabetes drugs.
Then they became weight loss blockbusters.
Now?
They're turning into the first mainstream longevity drugs—and they're redefining medicine itself.
Let’s break it down. 🧵 (Not Medical Advice! Consult your Doctor)
Then they became weight loss blockbusters.
Now?
They're turning into the first mainstream longevity drugs—and they're redefining medicine itself.
Let’s break it down. 🧵 (Not Medical Advice! Consult your Doctor)
February 9, 2026 at 1:27 PM
GLP-1s started as diabetes drugs.
Then they became weight loss blockbusters.
Now?
They're turning into the first mainstream longevity drugs—and they're redefining medicine itself.
Let’s break it down. 🧵 (Not Medical Advice! Consult your Doctor)
Then they became weight loss blockbusters.
Now?
They're turning into the first mainstream longevity drugs—and they're redefining medicine itself.
Let’s break it down. 🧵 (Not Medical Advice! Consult your Doctor)
A new contender posts up to 31.3% preclinical weight loss for a new small molecule drug candidate in combination with semaglutide
www.biopharmatrend.com/artificial-i...
www.biopharmatrend.com/artificial-i...
Beyond GLP-1: A New Combination Strategy Shows Up to 31.3% in Preclinical Study
www.biopharmatrend.com
February 3, 2026 at 12:04 PM
A new contender posts up to 31.3% preclinical weight loss for a new small molecule drug candidate in combination with semaglutide
www.biopharmatrend.com/artificial-i...
www.biopharmatrend.com/artificial-i...
Big news for the longevity industry!
It’s arguably the first clinical trial explicitly built on the idea of cellular rejuvenation as a longevity mechanism, and if it holds to the promise, it could be a big deal
www.biopharmatrend.com/news/fda-gre...
It’s arguably the first clinical trial explicitly built on the idea of cellular rejuvenation as a longevity mechanism, and if it holds to the promise, it could be a big deal
www.biopharmatrend.com/news/fda-gre...
FDA Greenlights First Human Trial of Epigenetic ‘Rejuvenation’ Therapy for Vision Loss
www.biopharmatrend.com
January 28, 2026 at 3:02 PM
Big news for the longevity industry!
It’s arguably the first clinical trial explicitly built on the idea of cellular rejuvenation as a longevity mechanism, and if it holds to the promise, it could be a big deal
www.biopharmatrend.com/news/fda-gre...
It’s arguably the first clinical trial explicitly built on the idea of cellular rejuvenation as a longevity mechanism, and if it holds to the promise, it could be a big deal
www.biopharmatrend.com/news/fda-gre...
If the claim holds up, it’s an important signal for genetic medicine.
www.biopharmatrend.com/artificial-i...
www.biopharmatrend.com/artificial-i...
This Company Claims World-First Ai Models For Programmable Gene Insertion
www.biopharmatrend.com
January 28, 2026 at 1:35 PM
If the claim holds up, it’s an important signal for genetic medicine.
www.biopharmatrend.com/artificial-i...
www.biopharmatrend.com/artificial-i...
Yes, this moment has come... 💊
www.biopharmatrend.com/news/novo-no...
www.biopharmatrend.com/news/novo-no...
Novo Nordisk Scores Major Win as Oral Weight-Loss Pill Gets FDA Nod — and the Race for Obesity Drugs Just Got Hotter
www.biopharmatrend.com
December 23, 2025 at 12:42 PM
Yes, this moment has come... 💊
www.biopharmatrend.com/news/novo-no...
www.biopharmatrend.com/news/novo-no...
Guess what they are...?
www.biopharmatrend.com/business-int...
www.biopharmatrend.com/business-int...
Three Big Ideas in Aging Research That Could Shift the Therapeutic Landscape
www.biopharmatrend.com
October 20, 2025 at 11:34 AM
Guess what they are...?
www.biopharmatrend.com/business-int...
www.biopharmatrend.com/business-int...
When two foundational technologies collide... they may pave the way into the future of biotech
www.biopharmatrend.com/business-int...
www.biopharmatrend.com/business-int...
AI and CRISPR—converging revolutions in biomedicine?
www.biopharmatrend.com
October 13, 2025 at 8:49 PM
When two foundational technologies collide... they may pave the way into the future of biotech
www.biopharmatrend.com/business-int...
www.biopharmatrend.com/business-int...
Сlinical trials designed without integration of relevant and informative biomarkers are 12 times more likely to fail...
www.biopharmatrend.com/artificial-i...
www.biopharmatrend.com/artificial-i...
How Lantern Pharma's AI-driven Approach Enables Precision Oncology
Explore how Lantern Pharma revolutionizes the field of precision oncology using its AI-driven RADR® platform. Uncover how the company leads the way in AI drug discovery and successfully tackles the co...
www.biopharmatrend.com
October 9, 2025 at 11:58 AM
Сlinical trials designed without integration of relevant and informative biomarkers are 12 times more likely to fail...
www.biopharmatrend.com/artificial-i...
www.biopharmatrend.com/artificial-i...
Surprising to see SPACs again, after I thought this financial vehicle got out of fashion... but here we go.
www.biopharmatrend.com/news/singapo...
www.biopharmatrend.com/news/singapo...
Singapore’s Nanyang Biologics Plans to Go Public on Nasdaq in US $1.5 Billion SPAC Deal
www.biopharmatrend.com
October 2, 2025 at 3:59 PM
Surprising to see SPACs again, after I thought this financial vehicle got out of fashion... but here we go.
www.biopharmatrend.com/news/singapo...
www.biopharmatrend.com/news/singapo...
Reposted by Andrii Buvailo, PhD
An article in BioPharmaTrend highlighted our recent earnings report, including “progress on internal assets REC-1245 (RBM39 degrader) and REC-617 (CDK7 inhibitor), alongside a $7 million milestone payment from Sanofi for a partnered immunology program.” www.biopharmatrend.com/news/recursi...
August 19, 2025 at 2:31 PM
An article in BioPharmaTrend highlighted our recent earnings report, including “progress on internal assets REC-1245 (RBM39 degrader) and REC-617 (CDK7 inhibitor), alongside a $7 million milestone payment from Sanofi for a partnered immunology program.” www.biopharmatrend.com/news/recursi...
AI in biotech is all about shifting from mainstream reductionism to holism...
www.biopharmatrend.com/business-int...
www.biopharmatrend.com/business-int...
17 Companies Pioneering AI Foundation Models in Pharma and Biotech
www.biopharmatrend.com
October 2, 2025 at 10:43 AM
AI in biotech is all about shifting from mainstream reductionism to holism...
www.biopharmatrend.com/business-int...
www.biopharmatrend.com/business-int...
Gene therapies sometimes fail, but when they work they are beautiful.
www.biopharmatrend.com/news/uniqure...
www.biopharmatrend.com/news/uniqure...
uniQure Reports Trial Success for Experimental Huntington’s Disease Gene Therapy
www.biopharmatrend.com
September 25, 2025 at 7:10 PM
Gene therapies sometimes fail, but when they work they are beautiful.
www.biopharmatrend.com/news/uniqure...
www.biopharmatrend.com/news/uniqure...
They say, #Canada has some serious edge when it comes to AI innovation... I also see in drug discovery, no?
www.biopharmatrend.com/news/merck-e...
www.biopharmatrend.com/news/merck-e...
Merck Expands Variational AI Collaboration To Up-To-$349M Deal On Two Small-Molecule Targets
www.biopharmatrend.com
September 23, 2025 at 3:59 PM
They say, #Canada has some serious edge when it comes to AI innovation... I also see in drug discovery, no?
www.biopharmatrend.com/news/merck-e...
www.biopharmatrend.com/news/merck-e...
Salt AI Raises $10M for Drag-and-Drop Platform to Build AI Workflows in Life Sciences
www.biopharmatrend.com
September 22, 2025 at 3:32 PM
Integra Therapeutics Raises €10.7 Million to Advance Gene Writing Platform and CAR-T Validation
www.biopharmatrend.com
September 19, 2025 at 9:57 PM
Gen AI for designing phages -- viruses that can infect and kill bacteria. A huge opportunity in fighting antibiotic resistance...
www.biopharmatrend.com/news/stanfor...
www.biopharmatrend.com/news/stanfor...
Stanford–Arc Team Reports AI-Made Viruses That Kill Bacteria
www.biopharmatrend.com
September 17, 2025 at 10:25 PM
Gen AI for designing phages -- viruses that can infect and kill bacteria. A huge opportunity in fighting antibiotic resistance...
www.biopharmatrend.com/news/stanfor...
www.biopharmatrend.com/news/stanfor...